Evofem Bio has launched its Phase 2b/3 clinical trial Amprevence and is accepting enrollees to see how its non-hormonal, on-demand and surfactant-free drug Amphora helps in the prevention of female gonorrhea and urogenital chlamydia.
The trial will enroll nearly 850 women in about 20 American cities. The key goal is to prevent the spread of the Chlamydia trachomatis bacteria; the secondary goal is to prevent the spread of the Neisseria gonorrhoeae infection.
Ampower, the phase 3 study, will look at preventing pregnancy with the Amphora Contraceptive Vaginal Gel with enrollment beginning in the next few weeks.
Data information should be available come early 2019.
Amphora is a vaginal contraceptive and can help prevent certain STDs. It’s been given the status of Qualified Infectious Disease Product for its work in decreasing recurring bacterial vaginosis and preventing urogenital gonorrhea.
Here’s what we've been up to recently.
